Softwr

Healthcare · head to head

Aidoc vs Therapixel

Aidoc logo

Aidoc

Healthcare

FDA cleared radiology AI for triage and notification of time critical findings

From
On request
Rated
-
Therapixel logo

Therapixel

Healthcare

French mammography AI with FDA clearances for 2D and tomosynthesis breast screening

From
On request
Rated
-

The short version

  • Each has a real cost: Aidoc the clearances are for triage and notification in the CADt category, so the software may reorder a worklist but may not deliver a diagnosis or replace a read, and business cases built on reduced radiologist workload do not survive contact with the regulatory wording.; Therapixel european and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • They diverge on capability: Aidoc covers Triage and notification, Therapixel covers MammoScreen 2D.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Aidoc and Therapixel actually diverge.

Attributes where Aidoc and Therapixel differ
AttributeAidocTherapixel
PlatformsWeb, iOS, AndroidWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Aidoc

  • Triage and notification
  • Intracranial haemorrhage
  • Pulmonary embolism
  • Large vessel occlusion
  • Pneumothorax on X-ray
  • aiOS platform
  • Clinical workflow notifications

Only in Therapixel

  • MammoScreen 2D
  • MammoScreen DBT
  • One to ten suspicion score
  • Summary report
  • Workstation and PACS delivery
  • Reading workflow configurations

What people use each for

The jobs each tool is most often brought in to do.

Aidoc

  • A regional stroke centre that wants large vessel occlusion flagged and the neurointervention team notified before the radiologist dictatesnot Therapixel
  • A trauma centre wanting cervical spine fracture and intra abdominal free gas prioritised in an overnight queue read by one on call radiologistnot Therapixel
  • An oncology imaging programme that wants incidental pulmonary embolism caught on staging CTs ordered for a different questionnot Therapixel
  • A health system that has bought AI from several vendors and wants one PACS integration through aiOS rather than one integration per algorithmnot Therapixel

Therapixel

  • A European breast screening programme running mandatory double reading that wants to evaluate AI as a concurrent or second reader within what national guidance permitsnot Aidoc
  • An American breast centre that has moved to tomosynthesis and needs reading support on DBT specifically, which Therapixel holds a clearance fornot Aidoc
  • A screening service wanting a graded suspicion score rather than a binary flag so readers can calibrate their own thresholdnot Aidoc
  • A radiology group evaluating multiple mammography AI vendors head to head on their own historic case set before committingnot Aidoc

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Aidoc

  • The clearances are for triage and notification in the CADt category, so the software may reorder a worklist but may not deliver a diagnosis or replace a read, and business cases built on reduced radiologist workload do not survive contact with the regulatory wording.
  • Triage algorithms are tuned for sensitivity, so false positives are routine, and each one interrupts a radiologist. Sites that do not measure positive predictive value in their own case mix see clinician trust erode within months.
  • Pricing is per algorithm and per study volume with no published rate card, so the cost of a multi algorithm deployment escalates sharply and cannot be benchmarked before a sales conversation.
  • The clinical benefit accrues to stroke, trauma and cardiology service lines while the cost usually lands in the radiology or IT budget, which makes internal funding harder than the return on investment slides suggest.
  • Performance depends on scanner protocols and reconstruction settings, so results validated at one site do not transfer, and each deployment needs local validation work that is rarely budgeted for.

Therapixel

  • European and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • MammoScreen does mammography only, so a hospital wanting AI across head CT, chest and breast needs several vendors and several PACS integrations, or an orchestration layer bought from someone else.
  • Therapixel is a small French company competing against Hologic and iCAD, which have incumbency inside the mammography reading workstation, so integration into an American breast centre is more work than it is for the workstation vendor own AI.
  • Detection performance is sensitive to the mammography unit vendor and acquisition protocol, so published results do not transfer between estates and each site needs local validation it must fund itself.
  • Whether AI can substitute for one of two human readers is a national workforce and liability question, not a product capability, so the labour saving that justifies the purchase in one country is not permitted in another.

Pricing, plan by plan

Aidoc

On request
  • Aidoc$undefined/year
    • Annual subscription priced by algorithm and by study volume
    • aiOS platform integration licensed separately from individual algorithms
    • Multi algorithm bundles negotiated for enterprise deployments

Therapixel

On request
  • MammoScreen$undefined/year
    • Priced per examination or by annual screening volume
    • 2D and tomosynthesis licensed by the versions cleared for each
    • Cloud or on premises deployment quoted differently

Which should you pick?

Choose Aidoc if

  • You need triage and notification.
  • You work on Web, iOS, Android.
  • You also want intracranial haemorrhage.

Choose Therapixel if

  • You need mammoscreen 2d.
  • You also want mammoscreen dbt.

Questions people ask

Is Aidoc or Therapixel better?
Neither clearly leads. Aidoc starts at On request and Therapixel at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Aidoc or Therapixel?
Aidoc starts at On request and Therapixel at On request.
Does Aidoc or Therapixel run on more platforms?
Aidoc runs on Web, iOS, Android. Therapixel runs on Web.
What is Aidoc best used for?
Aidoc is most often used for a regional stroke centre that wants large vessel occlusion flagged and the neurointervention team notified before the radiologist dictates, a trauma centre wanting cervical spine fracture and intra abdominal free gas prioritised in an overnight queue read by one on call radiologist, an oncology imaging programme that wants incidental pulmonary embolism caught on staging cts ordered for a different question, a health system that has bought ai from several vendors and wants one pacs integration through aios rather than one integration per algorithm. Of those, a regional stroke centre that wants large vessel occlusion flagged and the neurointervention team notified before the radiologist dictates and a trauma centre wanting cervical spine fracture and intra abdominal free gas prioritised in an overnight queue read by one on call radiologist are not what Therapixel is typically brought in for.
What can Aidoc do that Therapixel cannot?
Aidoc covers Triage and notification, Intracranial haemorrhage, Pulmonary embolism, Large vessel occlusion. Therapixel covers MammoScreen 2D, MammoScreen DBT, One to ten suspicion score, Summary report.

Answered from the vendors’ own pages

Aidoc: Is Aidoc FDA cleared?

Yes, it holds multiple 510(k) clearances, but they are for computer aided triage and notification. It may prioritise a worklist and notify a team. It may not provide a diagnostic interpretation or replace a radiologist read.

Therapixel: Is MammoScreen FDA cleared?

Yes. It holds 510(k) clearance K192854 for two dimensional mammography from July 2020, a November 2021 clearance for digital breast tomosynthesis, and two further clearances in October 2024 for later versions.

Aidoc: Does it reduce radiologist workload?

No. Every study still needs a full read. The benefit is in the order studies are read and how quickly a receiving specialty is activated, not in reading fewer studies.

Therapixel: Is it CE marked?

Yes, but European buyers should ask specifically for the current certificate under the Medical Device Regulation and its expiry date, because this class of diagnostic AI moved to a higher classification under MDR.

Aidoc: Can I run other vendors AI through it?

Yes, that is what the aiOS platform layer is for, and for health systems with several AI vendors it is often the main reason to buy Aidoc at all.

Therapixel: What does the one to ten score mean?

It is a graded suspicion score per finding and per study, designed to be integrated alongside a radiologist BI-RADS assessment rather than treated as a positive or negative result.

Aidoc: Is pricing published?

No. It is quoted per algorithm and by annual study volume, and enterprise bundles are negotiated case by case.

Therapixel: Does it cover anything besides mammography?

No. It is a mammography product only, including tomosynthesis. Other body regions need a different vendor.

Share

Related pages

Other head to heads